KLK6 has been implicated in EMT in breast cancer (Pampalakis et al., 2009), in gastric cancer by reducing the expression of E‐cadherin at the transcriptional level (Kim et al., 2012), and in colon cancer (Kim et al., 2011). Here, KLK6 is linked to colonic neoplasm.